Tests IOV-4001 cell infusion in adults with melanoma or lung cancer
Tests an infusion of IOV-4001 cells in adults with melanoma or lung cancer.
Key facts
- Who runs it
- Iovance Biotherapeutics, Inc.
- Where
- Cincinnati, Los Angeles, Louisville, Miami, Milwaukee, New York, Orlando, Pittsburgh, Tampa, and Westwood, United StatesSee the 11 sites
- Trial code
- Registry title
- A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 53 people, planned
- Started
- 20 Jul 2022
- Expected to end
- Sept 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- IOV-4001
- Record updated
- 11 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with melanoma that cannot be removed by surgery or has spread, or with stage III or IV non-small-cell lung cancer, who have already had other treatment.
- Age
- 18 to 70 years. People over 70 may join after the investigator discusses it with the medical monitor.
- Sex
- All sexes can join.
- Disease stage
- Stage IIIC, IIID or IV melanoma that cannot be removed by surgery or has spread, or stage III or IV non-small-cell lung cancer. At least one lesion that can be removed by surgery and at least one measurable lesion after that surgery. ECOG performance status of 0 or 1.
- Earlier treatment
- Melanoma: the cancer grew within 12 weeks of the last dose of an anti-PD-1/PD-L1 antibody, and a BRAF/MEK inhibitor if there is a BRAF mutation. Lung cancer: no more than 3 earlier lines of treatment, with growth after anti-PD-1/PD-L1 antibody or, for oncogene-driven tumors, after targeted therapy plus platinum chemotherapy or the antibody.
- Biomarker or test result
- People with a BRAF mutation must have had a BRAF/MEK inhibitor.
Main reasons for not taking part
- Melanoma that started in the eye (uveal/ocular)
- Symptomatic brain metastases that have not been treated
- Earlier organ transplant from a donor, or cell therapy with conditioning chemotherapy, in the past 20 years
- Need for steroid treatment of 10 mg/day prednisone or more
- Primary immunodeficiency, or another cancer in the past 3 years
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Participants must have a confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or metastatic melanoma or Stage III or IV NSCLC
- Participants who have received the following previous therapy:; Cohort 1 (Melanoma): Participants who have progressed within 12 weeks of last dose of anti-PD-1/PD-L1 blocking antibody and received BRAF/MEK inhibitor in those with BRAF mutations; Cohort 2 (NSCLC): Participants who should have received no more than 3 prior lines of therapy and:; those without oncogene-driven tumors: Have progressed within 12 weeks after last dose of anti-PD-1/PD-L1 blocking antibody; those with oncogene-driven tumors: Have progressed during/after ≥1 targeted therapy AND either:; platinum doublet chemotherapy; Or within 12 weeks after last dose of anti-PD-1/PD-L1 blocking antibody
- Participants who have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Participants who is assessed as having at least one resectable lesion
- Participants who have at least one measurable lesion, following resection of the lesion for IOV-4001 generation
- Participants who have adequate organ function
- Cardiac function test required
- Pulmonary function test may be required
- Participants of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control during treatment and up to 12 months
- Participants who are >70 years of age may be allowed to enroll after the investigator discusses with the medical monitor
Who cannot take part
- Participants who have had a history of allogeneic organ transplant or any form of cell therapy involving prior conditioning chemotherapy within the past 20 years
- Participants who require systemic steroid therapy 10 mg/day prednisone or another steroid equivalent dose
- Participants who have another primary malignancy within the previous 3 years
- Participants who have received or will receive a live or attenuated vaccination within 28 days prior to the start of the NMA-LD
- Participants who have melanoma of uveal/ocular origin
- Participants who have symptomatic untreated brain metastases
- Participants who have any form of primary immunodeficiency
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in United States
- University of CincinnatiCincinnati, United StatesContact: Iovance Biotherapeutics Study TeamTaking people
- The Angeles Clinic and Research InstituteLos Angeles, United StatesContact: Iovance Biotherapeutics Study TeamTaking people
- University of LouisvilleLouisville, United StatesContact: Iovance Biotherapeutics Study TeamTaking people
- Sylvester Comprehensive Cancer Center*Miami, United StatesContact: Iovance Biotherapeutics Study TeamTaking people
- Medical College of WisconsinMilwaukee, United StatesContact: Iovance Biotherapeutics Study TeamNo longer taking part
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Iovance Biotherapeutics Study TeamTaking people
- Weill Medical College of Cornell UniversityNew York, United StatesContact: Iovance Biotherapeutics Study TeamTaking people
- Orlando Health Cancer InstituteOrlando, United StatesContact: Iovance Biotherapeutics Study TeamTaking people
- UPMC Hillman Cancer CenterPittsburgh, United StatesContact: Iovance Biotherapeutics Study TeamTaking people
- Moffitt Cancer CenterTampa, United StatesContact: Iovance Biotherapeutics Study TeamTaking people
- The University of Kansas Cancer CenterWestwood, United StatesContact: Iovance Biotherapeutics Study TeamTaking people
About the trial
What the trial wants to find out
This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).
The 2 groups in the trial
- Cohort 1Treatment being tested
Participants with unresectable or metastatic melanoma
Treatment: IOV-4001
- Cohort 2Treatment being tested
Participants with Stage III or IV non-small-cell lung cancer
Treatment: IOV-4001
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
- Plain-language title
- Tests IOV-4001 cell infusion in adults with melanoma or lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05361174, who can take part
- Record updated
- 11 June 2026